Drugs / EGEN-001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00473954 | Apr 2007 → Nov 2009 | ovarian neoplasm | EGEN, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00137865 | Aug 2005 → Oct 2006 | ovarian neoplasm | EGEN, Inc. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01300858 | Jun 2011 → Jul 2014 | colorectal cancer | EGEN, Inc. | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-11-29 | Imunon | Results Celsion Corporation Announces ASCO 2015 GEN-1 Immunotherapy Phase 1b Results in Ovarian Cancer Presentation imunon.com ↗
The findings demonstrated an overall clinical benefit of 57% for all treatment arms, with a parti |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-11-29 | Imunon | Celsion Corporation Announces ASCO 2015 GEN-1 Immunotherapy Phase 1b Results in Ovarian Cancer Presentation imunon.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGEN-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00473954 ↗ |
| Known as | phIL-12-005/PPC | “EGEN-001 (phIL-12-005/PPC)” NCT00473954 ↗1“EGEN-001 (phIL-12-005/PPC)” NCT00137865 ↗ |
| Action | Restore | “contains the human gene for the cytokine interleukin-12 (IL-12) in a special carrier system designed to enter the cells and help the body to produce cytokines” NCT00473954 ↗ |
| Modality | Other / unclassified | “investigational gene transfer agent EGEN-001 (phIL-12-005/PPC)” NCT00137865 ↗ |
| Route | Other | “administered directly into the peritoneal cavity” NCT00473954 ↗ |